From Oncogenomics we promote the application of the most advanced genomic developments in the field of Medical Oncology, favoring innovation in clinical practice, especially in the selection of personalized treatments.
We focus our activity on offering a fast and quality service to perform the Prosigna® Test (PAM50) developed by NanoString, working with the only Spanish laboratory accredited to carry out the test.
The Prosigna® Test (PAM50) is the only diagnostic test that informs your oncologist of the intrinsic tumor subtype and also provides the individualized probability of recurrence at a distance of 10 years, the risk of recurrence (ROR) and the category of risk.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Calle De Arturo Soria, 17, Madrid,comunidad De Madrid,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- oncogenomics.es
- Keywords
- Oncogenómica, Oncología, PAM 50, Genética, Diagnostico Cáncer de Mama, Test Genetico, Oncología personalizada.
- HQ
- Madrid, Comunidad de Madrid
Oncogenomics Questions
Oncogenomics's website is oncogenomics.es
Oncogenomics's LinkedIn profile is https://es.linkedin.com/company/oncogenomics-spain
Oncogenomics has
3 employees.
View email and phone details for 3
employees at Oncogenomics.
Oncogenomics's industry is
Biotechnology Research
Oncogenomics's categories are Biotechnology Research
Oncogenomics's founding year is 2014
